First patients test experimental cancer drug in early safety trial
NCT ID NCT06108479
Summary
This first-in-human study tested the safety of a new cancer drug called DF6215, both alone and combined with an existing immunotherapy (pembrolizumab), in adults with advanced solid tumors that couldn't be removed by surgery, had returned, or had spread. The main goals were to find safe dose levels and check for side effects in 35 participants. This was an early Phase 1 trial, so it focused on safety rather than proving how well the treatment works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Marseille - Hôpital de la Timone
Marseille, 13005, France
-
Cancer Research SA (CRSA)
Adelaide, South Australia, 5000, Australia
-
Centre Georges François Leclerc
Dijon, 21000, France
-
Centre Hospitalier Universitaire de Bordeaux
Bordeaux, 33075, France
-
Centre Hospitalier Universitaire de Poitiers
Poitiers, 86000, France
-
Hôpital Lyon-Sud
Pierre-Bénite, 69495, France
-
Institut Bergonié
Bordeaux, 33000, France
-
Institut Curie
Paris, 75005, France
-
Institut Paoli-Calmettes
Marseille, 13009, France
-
Institut Universitaire du Cancer de Toulouse Oncopole
Toulouse, 31100, France
-
Institut de Cancérologie de l'Ouest - Saint-Herblain - Site René Gauducheau
Saint-Herblain, 44805, France
-
Lifespan - Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
NYU Langone Health
New York, New York, 10016, United States
-
Peninsula and South East Oncology Medical (PASO)
Frankston, Victoria, 3199, Australia
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Sarcoma Oncology Center
Santa Monica, California, 90403, United States
-
Tampa General Hospital
Tampa, Florida, 33606, United States
-
The Angeles Clinic and Research Institute - West Los Angeles Office
Los Angeles, California, 90025, United States
-
University of California Irvine Medical Center
Orange, California, 92868, United States
-
University of California San Diego Moores Cancer Center
San Diego, California, 92093, United States
Conditions
Explore the condition pages connected to this study.